Last reviewed · How we verify
STREPTOKINASE
Streptokinase is a marketed drug used for breaking down blood clots through the activation of plasminogen. Its key strength lies in its well-established mechanism and long-standing use in clinical practice. The primary risk is the expiration of the key composition patent in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | STREPTOKINASE |
|---|---|
| Modality | Enzyme |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
| First approval | 1997 |
Approved indications
Common side effects
Key clinical trials
- Effect of Thrombolysis on 30-day Mortality in Intermediate High Risk Pulmonary Patients With Low Bleeding Risk (NA)
- To Compare the Efficacy & Safety of Ultra-Slow (24 hr) Low Dose (25 mg) Infusion of Alteplase Over Slow (24hr) Infusion of Streptokinase in Mechanical Prosthetic Valve Thrombosis (NA)
- Systemic Thrombolysis Versus Catheter Directed Management for Acute Intermediate-high Pulmonary Embolism
- Extracorporeal Life Support and Modification of Hemostasis
- Asia Africa Streptokinase Trial (PHASE2)
- Catheter-Directed Pulmonary Reperfusion in Treatment of Pulmonary Embolism Patients (NA)
- A Trial Using Double-Bolus THR-100 Versus Streptokinase (PHASE3)
- Clinical Trial to Assess the Efficacy and Safety of MUCOLASE Tablet(Streptokinase • Streptodornase) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- STREPTOKINASE CI brief — competitive landscape report
- STREPTOKINASE updates RSS · CI watch RSS